The supply will cover the needs of the Galician program for early detection of cervical cancer, through analyses aimed at identifying virus genotypes capable of causing pre-cancerous lesions and cancer. The contract, lasting four years, includes the necessary reagents, materials, and the provision of equipment for processing samples.
Tests can be performed using samples obtained via liquid cytology or collected by participants themselves using a self-sampling device. This latter method facilitates program participation by allowing women to collect samples without direct involvement from a healthcare professional.
Molecular detection of high-risk (oncogenic) HPV genotypes helps identify infections associated with a higher risk of developing pre-cancerous cervical lesions and determine the need for complementary tests when appropriate.
The Galician program for early detection of cervical cancer is a public, voluntary, and free initiative aimed at women aged 25 to 65. It began as a pilot project in late 2020 and was progressively rolled out across Galicia by December 2023.
This population screening focuses on preventing cervical cancer and its pre-cancerous lesions by detecting human papillomavirus infection, the cause of most cases. While there are over 200 virus variants, only a few high-risk ones can cause neoplasia. Early detection allows for the identification and treatment of pre-cancerous lesions before they develop into cancer, significantly increasing the chance of cure. The HR-HPV test offers higher sensitivity and negative predictive value than cytology.
This prevention tool is complemented by HPV vaccination, offered by Galicia since 2008. The combined goal of these actions is to reduce the incidence and mortality associated with cervical cancer and improve the health of Galician women.




